Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Asthma Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma

NCT04108377
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

NCT05421598
View directory record Official record
Conditions
Asthma
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jun 26, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Pilot Study of Magnesium Infusions in Pediatric Asthma

NCT01522040
View directory record Official record
Conditions
Asthma
Interventions
Magnesium Sulfate, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

NCT00207740
View directory record Official record
Conditions
Asthma
Interventions
CNTO148, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • Stockton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Jun 26, 2026, 4:15 AM EDT
Completed No phase listed Observational Results available

Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)

NCT00590005
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
6 Years to 21 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jun 26, 2026, 4:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device

NCT05592769
View directory record Official record
Conditions
Respiratory Disease
Interventions
HealthBeacon Injection Care Management System (ICMS)
Device
Lead sponsor
HealthBeacon Plc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

NCT01402986
View directory record Official record
Conditions
Asthma
Interventions
Placebo Q2W, Tralokinumab 300 mg, Q2W, Placebo, Q2/4W, Tralokinumab 300 mg, Q2/4W
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

NCT02918071
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Teva Asthma Predictive Analytics Study

NCT04997304
View directory record Official record
Conditions
Asthma
Interventions
AirDuo Digihaler, ProAir Digihaler
Combination Product
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Not listed No phase listed Observational

The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy

NCT01776177
View directory record Official record
Conditions
Allergic Asthma
Interventions
Not listed
Lead sponsor
Joseph D. Diaz, MD
Industry
Eligibility
12 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

NCT02918019
View directory record Official record
Conditions
Asthma
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jun 26, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581
View directory record Official record
Conditions
Asthma
Interventions
PF-07275315, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTMB Research on Severe Asthma (UROSA) Study

NCT02264691
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jun 26, 2026, 4:15 AM EDT
Terminated Not applicable Interventional

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

NCT05848115
View directory record Official record
Conditions
Asthma in Children
Interventions
Bi-level Positive Airway Pressure, Sham Bi-level Positive Airway Pressure
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional Results available

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

NCT04669288
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Months to 60 Months
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

NCT01603277
View directory record Official record
Conditions
Moderate-to-Severe Asthma
Interventions
Anti-GM-CSF Monoclonal Antibody 400mg, Placebo
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jun 26, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation

NCT01515995
View directory record Official record
Conditions
Asthma
Interventions
Nebulized magnesium sulfate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Jun 26, 2026, 4:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

NCT07359846
View directory record Official record
Conditions
Severe Asthma
Interventions
GB-0895, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
12 Years to 80 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Bakersfield, California • Inglewood, California • West Covina, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 26, 2026, 4:15 AM EDT